ANAPLASTIC THYROID CANCER: CLINICAL OUTCOMES WITH CONFORMAL RADIOTHERAPY

被引:83
作者
Bhatia, Aarti [1 ]
Rao, Archana [1 ]
Ang, Kie-Kian [1 ]
Garden, Adam S. [1 ]
Morrison, William H. [1 ]
Rosenthal, David I. [1 ]
Evans, Douglas B. [3 ]
Clayman, Gary [4 ]
Sherman, Steven I. [5 ]
Schwartz, David L. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Expt Diagnost Imaging, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2010年 / 32卷 / 07期
关键词
thyroid cancer; anaplastic; radiotherapy; IMRT; conformal; SINGLE INSTITUTION; PHASE-II; CARCINOMA; CHEMOTHERAPY; SURVIVAL; SURGERY; DOXORUBICIN; EXPERIENCE;
D O I
10.1002/hed.21257
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 [耳鼻咽喉科学];
摘要
Background. The aim of this study was to review institutional outcomes for anaplastic thyroid cancer treated with conformal 3-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT). Methods. In all, 53 consecutive patients were analyzed. Thirty-one (58%) patients were irradiated with curative intent. Median radiation dose was 55 Gray (Gy; range, 4-70 Gy). Thirteen (25%) patients received IMRT to a median 60 Gy (range, 39.9-69.0 Gy). Thirty-nine (74%) patients received chemotherapy with radiation. Results. The Kaplan-Meier estimate of overall survival (OS) at 1 year for definitively irradiated patients was 29%. Patients without distant metastases receiving >= 50 Gy had superior survival outcomes; 5 such patients had no evidence of disease at last follow-up. Use of IMAT versus 3DRT did not influence toxicity. Conclusions. Outcomes for anaplastic thyroid cancer treated with 3DRT or IMRT remain equivalent to historical results. Healthy patients with localized disease who tolerate full dose irradiation can potentially enjoy prolonged survival. Biologically targeted radiosensitization merits prioritized investigation. (c) 2009 Wiley Periodicals, Inc. Head Neck 32: 829-836, 2010
引用
收藏
页码:829 / 836
页数:8
相关论文
共 28 条
[1]
Ain KB, 1999, SEMIN SURG ONCOL, V16, P64, DOI 10.1002/(SICI)1098-2388(199901/02)16:1<64::AID-SSU10>3.3.CO
[2]
2-L
[3]
Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches [J].
Are, C ;
Shaha, AR .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (04) :453-464
[4]
Effect of primary treatment on survival in anaplastic thyroid carcinoma [J].
Besic, N ;
Auersperg, M ;
Us-Krasovec, M ;
Golouh, R ;
Frkovic-Grazio, S ;
Vodnik, A .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (03) :260-264
[5]
Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years [J].
Brignardello, Enrico ;
Gallo, Marco ;
Baldi, Ileana ;
Palestini, Nicola ;
Piovesan, Alessandro ;
Grossi, Emidio ;
Ciccone, Giovannino ;
Boccuzzi, Giuseppe .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2007, 156 (04) :425-430
[6]
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study [J].
Cohen, Ezra E. W. ;
Rosen, Lee S. ;
Vokes, Everett E. ;
Kies, Merrill S. ;
Forastiere, Arlene A. ;
Worden, Francis P. ;
Kane, Madeleine A. ;
Sherman, Eric ;
Kim, Sinil ;
Bycott, Paul ;
Tortorici, Michael ;
Shalinsky, David R. ;
Liau, Katherine F. ;
Cohen, Roger B. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4708-4713
[7]
Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy [J].
De Crevoisier, R ;
Baudin, E ;
Bachelot, A ;
Leboulleux, S ;
Travagli, JP ;
Caillou, B ;
Schlumberger, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04) :1137-1143
[8]
Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope [J].
Deshpande, Hari A. ;
Gettinger, Scott N. ;
Sosa, Julie Ann .
CURRENT OPINION IN ONCOLOGY, 2008, 20 (01) :19-24
[9]
Dowlati A, 2002, CANCER RES, V62, P3408
[10]
Phase II trial of sorafenib in advanced thyroid cancer [J].
Gupta-Abramson, Vandana ;
Troxel, Andrea B. ;
Nellore, Anoma ;
Puttaswamy, Kanchan ;
Redlinger, Maryann ;
Ransone, Kathy ;
Mandel, Susan J. ;
Flaherty, Keith T. ;
Loevner, Laurie A. ;
O'Dwyer, Peter J. ;
Brose, Marcia S. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4714-4719